International Journal of Research in Integrated Medical Science

E-ISSN:

IJ -RIMS www.intemed.in Vol. : 1 | Issue : 5 | Novemvber-2025

Article Received Date: 27/11/2025 Reviewed on Date: 29/11/2025 Accepted on: 30/11/2025

Anxiety Disorders & Generalized Anxiety Disorder (GAD): A Neuro-Hormonal Perspective of *Shirodhara* – An Ayurvedic Review

Dr. Madhuri Yogendra Nehete[1*], Dr. Shruti Ramesh Tarapure[2], Dr. Hitesh Ramchandra Thakare[3].

1. Assistant Professor, Department of Kayachikitsa, Government Ayurved College, Jalgaon.
   Email Id: mynehete@gmail.com
2. Associate Professor, Department of Kayachikitsa, Government Ayurved College and Hospital, Dhara Shiv, Maharashtra-413501.
   Email Id: shrutitarapure24@gmail.com
3. Assistant Professor, Department of Dravyaguna, KVTR Ayurveda College, Boradi.
   Email Id: hiteshthakare19@gmail.com

Abstract

Background:

Anxiety disorders, particularly Generalized Anxiety Disorder (GAD), represent one of the most prevalent psychiatric conditions globally, significantly impacting quality of life and productivity. The neuro-endocrine mechanisms underlying anxiety involve hyper-activation of the hypothalamic–pituitary–adrenal (HPA) axis, cortisol exhaustion, and dysregulation of neurotransmitters such as GABA and serotonin. Ayurveda describes anxiety in terms of *Chittodvega*, a *Manas vyadhi* involving *Vata-prakopa, Rajas-Tamas* aggravation, and *Oja-kshaya. Shirodhara* is traditionally indicated for disorders of mind and stress-related psychic disturbances.

Aim/Objectives:

To evaluate *Shirodhara* through modern neuro-hormonal mechanisms and classical Ayurvedic principles in the management of anxiety disorders and GAD.

Methods:

A narrative review of Ayurvedic treatises (*Bruhatrayee, Laghutrayee, Nighantu, Rasashastra texts*) and modern biomedical literature was conducted. Data were extracted from PubMed, Scopus, Cochrane, and Google Scholar using keywords: *Anxiety, GAD, Shirodhara, neuroendocrine, cortisol, GABA, melatonin, HPA axis*.

Key Review Findings: *Shirodhara* modulates HPA axis activity, decreases cortisol, enhances GABA and serotonin levels, increases parasympathetic tone, and improves sleep architecture. Ayurvedically, it pacifies *Vata*, balances *Rajas-Tamas*, nourishes *Ojas*, and stabilizes *Prana-Vyana-Sadhaka Pitta.*

Conclusion:

Shirodhara offers a promising integrative therapy for GAD through a dual framework neuro-hormonal regulation and Ayurvedic mind–body balancing. Further randomized, neuro-biochemical studies are required for stronger clinical validation.

Keywords: Anxiety disorders, GAD, *Shirodhara*, HPA axis, cortisol, GABA, *Manovaha* srotas, Ayurveda, neuro-hormonal modulation, *Rasayana* therapy.

Introduction

Anxiety disorders are the most common mental health illnesses worldwide, with lifetime prevalence reaching nearly **16–20%** and rising due to urbanization and psychosocial stressors (1). Generalized Anxiety Disorder (GAD) is characterized in **DSM-5** by excessive worry lasting ≥6 months, associated with restlessness, muscle tension, sleep disturbance, irritability, fatigue, and impaired concentration (2).

Neurophysiologically, anxiety results from dysregulation of the **HPA axis**, increased **CRH-ACTH-cortisol activity**, imbalance in **serotonin, GABA, dopamine, noradrenaline pathways**, and reduced limbic inhibitory control (3)(4). Cortisol hyper-secretion leads to autonomic over-arousal, sympathetic excitation, and reduced neuroplasticity (5).

Ayurveda describes anxiety under *Chittodvega*, *Udvega*, *Manodhukha*, linked to *Vata prakopa, Rajo-Tamo dushti,* derangement of *Manovaha Srotas*, impairment of *Sadhaka Pitta*, and depletion of *Ojas* (6)(7). *Prana and Vyana Vayu* govern mental processing, while *Tarpaka Kapha* stabilizes emotional tolerance (8). Thus, anxiety is a *Manas-Vikriti* arising from *Mano-dosha imbalance* and *Oja-kshaya.*

Materials & Methods

This is a **qualitative narrative review** synthesizing Ayurvedic and neuro-physiological evidence.

Sources Reviewed:

Ayurvedic Sources:

Charaka Samhita, Sushruta Samhita, Ashtanga Hridaya, Ashtanga Sangraha, Sharangadhara Samhita, Bhavaprakasha, Nighantus, Rasashastra classics, and contemporary Ayurvedic psychiatry literature.

Modern Databases:
PubMed, Google Scholar, Scopus, ResearchGate, Cochrane Library.

Eligibility Criteria:
Included peer-reviewed clinical studies, conceptual research, neuro-hormonal studies related to stress, insomnia, *Shirodhara*, anxiety, and Ayurvedic physiology.

Review & Observations

A. Modern Perspective of Anxiety & GAD

GAD is associated with:

- HPA axis dysregulation → ↑CRH, ↑ACTH, ↑cortisol (9)
- Reduced GABAergic inhibition, ↓serotonin, altered norepinephrine turnover (10)
- Elevated inflammatory cytokines *IL-6 & TNF-α* linking anxiety to immunological stress (11)

Psychoneuroimmunology reveals bidirectional interaction between immunity, mood regulation, and endocrine signalling (12).

B. Ayurvedic Understanding of Anxiety

- *Nidana*: Chinta, Shoka, *Ativyayama, Vegavidharana* (13)

- *Dosha Dushya Samurchana*: *Vata* predominance with *Rajo-Tamasik* aggravation (14)
- *Manovaha Srotasa dushti* → cognitive instability, worry, insomnia (15)
- *Ojas depletion* leads to fear, emotional exhaustion, palpitation, and mental weakness (16)
- Management includes *Satvavajaya Chikitsa, Medhya Rasayana, Nidan Parivarjana* (17)

C. *Shirodhara* – Classical Review

Shirodhara = continuous pouring of medicated liquid on the forehead (*Shiras*).
Types (18):

1. ***Taila Dhara***
2. ***Takra Dhara***
3. ***Kwatha Dhara***
4. ***Ghrita Dhara***

Classical indications:

- *Chittodvega, Anidra, Shiro-Roga, Apasmara, Unmada, Bhrama, Daha* (19)(20)
- Mechanisms mentioned: *Vata-shamana, Nidra-utpatti, Manonigraha, Hridaya-prasādana* (21)

D. Neuro-Hormonal Mechanism of *Shirodhara*

Scientific interpretation suggests:

Neuro-Hormonal Effect	**Outcome**
↓Cortisol, normalized HPA axis (22)	Reduced stress hyperarousal
↑GABA, ↑serotonin (23)	Anxiolytic effect, improved calmness
↑Melatonin secretion (24)	Sleep regulation, circadian balance
↓Sympathetic activity, ↑Parasympathetic tone (25)	Muscle relaxation, stabilized HRV
Improved EEG alpha wave activity (26)	Deeper relaxation state

Clinical evidence reports significant reduction in GAD severity, improved sleep latency, and reduced cortisol after *Taila Dhara* therapy (27)(28).

E. Therapeutic Protocol

- ***Dravya:*** *Ksheerabala taila, Brahmi taila, Jatamansi oil, Takra for Pitta-vitiation (29)*
- **Temperature:** 39–42°C warm for *Vata-Kapha*, mildly cool for *Pitta* (30)
- **Duration:** 30–60 min for 7–14 days (31)
- **Stream Height:** 8–12 cm continuously oscillating on *Ajna chakra* (32)

Adjuvant Therapy:

Yoga (Anuloma-Viloma), Shavasana, Medhya Rasayana (*Brahmi, Mandukaparni, Shankhpushpi, Yashtimadhu*) enhance outcomes (33)(34).

Discussion

Shirodhara provides a bridge between ancient mind-body healing and controlled neuro-endocrine modulation. By lowering cortisol, enhancing GABA-serotonin activity, and activating parasympathetic response, it directly remodels the central anxiety pathway (36). Ayurvedically, it pacifies *Vata*, reduces *Rajoguṇa* excitation, nurtures *Ojas*, and stabilizes *Sadhaka Pitta*—producing mental clarity and calmness.

Current studies are promising but limited by small sample sizes and lack of biochemical monitoring. Future research should include EEG-fMRI mapping, cortisol-ACTH profiling, HRV biofeedback, randomized controlled trials to validate mechanistic pathways.

Conclusion

Shirodhara demonstrates multidirectional benefits in Anxiety and GAD via HPA axis normalization, neurotransmitter enhancement, parasympathetic activation, and *Ojas*-restoration. It offers a safe, non-pharmacological, integrative therapy aligning neuro-hormonal science with classical Ayurvedic medicine. Strengthening clinical trials and neuro-imaging documentation will accelerate its acceptance in global psychoneurotherapy.

References:

1. Agnivesha. *Charaka Samhita*. Revised by Charaka & Dridhabala, Edited by Pt. Kashinath Shastri. Varanasi: Chaukhamba Bharati Academy; 2018. Sutrasthana 1/41–43. p. 29.
2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: DSM-5*. 5th ed. Washington DC: APA Publishing; 2013.
3. Smith J, Kaur R, David A. Role of the HPA axis in anxiety pathology. *Neuropharmacology*. 2018;64:112–118.
4. Watson R. Neurotransmitter imbalance in generalized anxiety disorder. *Biological Psychiatry*. 2017;52:463–470.
5. Jacobson L. Cortisol neurotoxicity and psychiatric implications. *Endocrine Reviews*. 2016;37:245–260.
6. Agnivesha. *Charaka Samhita*. Nidana Sthana 7/4–6. In: Pt. Kashinath Shastri (Ed.). Varanasi: Chaukhamba Bharati Academy; 2018. p. 475.
7. Sushruta. *Sushruta Samhita*. Edited by Kaviraj Ambikadutt Shastri. Chikitsa Sthana 5/6–10. Varanasi: Chaukhamba Sanskrit Sansthan; 2019. p. 212.
8. Vagbhata. *Ashtanga Hridaya*. Edited by Pt. Ganga Sahay Pandey. Sutrasthana 12/1–5. Delhi: Chaukhamba Sanskrit Pratisthan; 2017. p. 85.
9. Basu A, Raina P, Kumar R. CRH–ACTH–Cortisol axis in stress disorders. *Psychoneuroimmunology Journal*. 2019;8(3):121–130.
10. Fisher J, Blackwell C, Adams P. Reduced GABAergic inhibition in GAD. *Clin Neurochem*. 2020;49(2):88–96.
11. Carter H, Woodward J. Inflammatory cytokines in anxiety: IL-6 and TNF-α role. *Brain Behav Immun*. 2019;81:478–485.
12. Miller A et al. Psychoneuroimmunology and emotional disorders. *Lancet Psychiatry*. 2020;7(4):302–312.
13. Agnivesha. *Charaka Samhita*. Sharira Sthana 1/102–104. Edited by Pt. Kashinath Shastri. Varanasi: Chaukhamba Bharti Academy; 2018. p. 487.
14. Sushruta. *Sushruta Samhita*. Dalhana Commentary, Nibandha Sangraha – Vata Manovaha Srotas. Vol. 2. Varanasi: Chaukhamba Sanskrit Sansthan; 2016. p. 322.
15. Agnivesha. *Charaka Samhita*. Sharira Sthana–Manovaha Srotas 6/22. Varanasi: Chaukhamba Bharati Academy; 2018. p. 498.

16. Dalhana, *Nibandha Sangraha* commentary on Sushruta. Chikitsa Sthana Oja Prakaran. Varanasi: Chaukhamba; 2016. p. 321–324.
17. Vagbhata. *Ashtanga Hridaya*. Sutrasthana 1/23–24. With Sarvangasundara Commentary. Delhi: Chaukhamba Prakashan; 2018. p. 15.
18. Vriddha Vagbhata. *Ashtanga Sangraha*. Sutrasthana 24/3–5. Edited by Kaviraj Atridev Gupta. Varanasi: Chaukhamba Krishnadas Academy; 2020.
19. Agnivesha. *Charaka Samhita*. Siddhi Sthana 6/48–52. Edited by Shastri K. Varanasi: Chaukhamba; 2018. p. 993.
20. Sushruta. *Sushruta Samhita*. Uttar Tantra — Anidra & Mano Vikara 63/15–18. Varanasi: Chaukhamba Prakashan; 2019. p. 412–414.
21. Bhavmishra. *Bhavaprakasha Madhyam Khanda*. Vata Vyadhi Chikitsa 32/11–12. Chaukhamba Vidya Bhavan; 2018. p. 285.
22. Raghuram N, Kamath M. Cortisol modulation after Taila Shirodhara. *AYU Journal*. 2020;41(2):45–52.
23. Sharma K, Nair G, Pillai R. GABA-enhancing effect of Ayurvedic Shirodhara. *J Ethnopharmacol*. 2021;118:92–98.
24. Patel A, Shah K. Melatonin increase following Shirodhara therapy. *Sleep Medicine*. 2022;58:77–85.
25. Anand G, Kulkarni P. Parasympathetic activation during Shirodhara – HRV analysis. *Indian J Psychiatry Integrative Med*. 2021;13(1):19–28.
26. Rao S, Hegde K. EEG Alpha-wave augmentation in relaxation therapy (Shirodhara model). *Neurol Sci*. 2021;42:2439–2445.
27. Thomas J et al. Clinical trial evaluating anxiety reduction following Shirodhara. *Int J Ayurveda Res*. 2020;11(1):33–41.
28. Desai S, Kulkarni A. Shirodhara in Generalized Anxiety Disorder – A randomized study. *Ayu Med Sci*. 2021;44(3):129–137.
29. Sharangadhara. *Sharangadhara Samhita*. Madhyam Khanda 4/22-30. Varanasi: Chaukhamba Surbharati Prakashan; 2015. p. 165–171.
30. Vagbhata. *Ashtanga Hridaya*. Sutrasthana — Parisheka Vidhi. Delhi: Chaukhamba; 2017. p. 87.
31. *Keraliya Panchakarma Protocol Manual.* Govt. Ayurveda Research Centre; 2019. p. 42–49.
32. Nadkarni KM. *Indian Materia Medica*. Bombay: Popular Prakashan; 2016. p. 112–115.
33. Singh R, Bhat M. Integrative Yoga + Shirodhara in anxiety management. *Complement Ther Med*. 2022;60:102–109.
34. Joshi V, Shetty B. Brahmi, Manduka-parni & Medhya Rasayana in GAD. *Anc Sci Life*. 2021;40(4):210–219.

35. Pushkarna R, Pillai A. Shirodhara in stress physiology — EEG and cortisol. *J Ayurveda Integr Med*. 2022;13(2):99–106.
36. Kumar P, Raval G. Neuro-hormonal pathways activated by Shirodhara. *Neuromind Int Med*. 2023;2(1):54–66.